Compugen Financials

CGEN Stock  USD 2.09  0.05  2.34%   
Based on the analysis of Compugen's profitability, liquidity, and operating efficiency, Compugen may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Compugen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 26th of January 2026, Non Current Liabilities Total is likely to grow to about 48.2 M, while Total Assets are likely to drop about 72.9 M.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Compugen Balance Sheet Chart

At this time, Compugen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 26th of January 2026, Non Current Liabilities Total is likely to grow to about 48.2 M, while Total Assets are likely to drop about 72.9 M.
Key indicators impacting Compugen's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.04480.061
Way Down
Slightly volatile
Current Ratio9.976.05
Way Up
Slightly volatile
Investors should never underestimate Compugen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Compugen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Compugen.

Net Income

(13.45 Million)

  
Build AI portfolio with Compugen Stock
Understanding current and past Compugen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Compugen's financial statements are interrelated, with each one affecting the others. For example, an increase in Compugen's assets may result in an increase in income on the income statement.

Compugen Stock Summary

Compugen competes with Innate Pharma, Nuvectis Pharma, Molecular Partners, Milestone Pharmaceuticals, and Rani Therapeutics. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Compugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINIL0010852080
Business AddressAzrieli Center, Holon,
SectorLife Sciences Tools & Services
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitecgen.com
Phone972 3 765 8585
CurrencyUSD - US Dollar

Compugen Key Financial Ratios

Compugen Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets132.2M94.2M121.3M115.0M132.2M72.9M
Other Current Liab11.7M9.5M11.0M8.2M9.5M10.0M
Net Debt(5.1M)(9.1M)(12.5M)(15.3M)(13.8M)(14.5M)
Retained Earnings(422.1M)(455.8M)(474.5M)(488.8M)(439.9M)(417.9M)
Accounts Payable4.6M1.8M3.5M1.8M2.1M1.9M
Cash7.8M11.1M13.9M18.2M21.0M24.8M
Net Receivables188K317K61.3M269K309.4K293.9K
Inventory(780K)(119.3M)(6.0M)(72.6M)(65.4M)(62.1M)
Total Liab25.5M16.5M55.8M60.1M69.1M72.5M
Total Current Assets123.2M86.1M114.6M106.0M121.9M128.0M
Common Stock239K240K247K248K285.2K299.5K
Other Liab5.6M5.5M6.4M3.3M3.8M4.6M
Other Assets3.2M4.7M5.0M4.7M5.4M5.7M
Other Current Assets6.0M2.5M2.6M2.5M2.2M2.9M
Short Term Debt768K613K632K448K403.2K802.3K
Net Tangible Assets38.3M119.8M106.7M77.7M89.3M77.0M
Net Invested Capital106.7M77.7M65.6M54.9M63.2M72.8M
Net Working Capital106.1M74.2M88.3M85.8M98.7M78.8M
Capital Stock239K240K247K248K285.2K244.5K

Compugen Key Income Statement Accounts

202120222023202420252026 (projected)
Interest Expense869K27K31K34K30.6K29.1K
Total Revenue6M7.5M33.5M27.9M32.0M33.6M
Gross Profit5.3M6.5M31.5M19.9M22.9M24.1M
Operating Income(35.1M)(35.4M)(13.0M)(14.9M)(13.4M)(14.1M)
Ebit(35.1M)(35.4M)(13.0M)(14.9M)(13.4M)(14.1M)
Research Development28.7M30.6M34.5M24.8M28.5M18.3M
Ebitda(34.6M)(34.9M)(12.5M)(14.4M)(13.0M)(13.6M)
Cost Of Revenue680K975K2.0M7.9M9.1M9.6M
Income Before Tax(34.2M)(33.6M)(9.8M)(9.7M)(8.7M)(9.2M)
Net Income(32.9M)(33.7M)(18.8M)(14.2M)(12.8M)(13.4M)
Income Tax Expense(1.3M)58K9.0M4.5M5.2M5.5M
Interest Income894K1.7M3.0M3.5M4.0M4.2M
Net Interest Income871K1.7M3.2M5.2M6.0M6.3M

Compugen Key Cash Accounts

202120222023202420252026 (projected)
Change In Cash704K2.9M2.8M4.0M4.6M4.8M
Free Cash Flow(23.0M)(35.0M)(36.1M)49.5M44.5M46.8M
Depreciation461K482K476K486K437.4K415.5K
Other Non Cash Items(573K)515K(452K)(1.7M)(1.6M)(1.5M)
Capital Expenditures292K487K172K118K106.2K100.9K
Net Income(34.2M)(33.7M)(18.8M)(14.2M)(12.8M)(13.4M)
End Period Cash Flow8.5M11.4M14.3M18.2M16.4M11.1M
Investments6.9M37.1M35.5M(46.3M)(53.2M)(50.5M)
Change To Netincome2.3M2.9M4.2M4.3M4.9M2.9M

Compugen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Compugen's current stock value. Our valuation model uses many indicators to compare Compugen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Compugen competition to find correlations between indicators driving Compugen's intrinsic value. More Info.
Compugen is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Compugen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Compugen's earnings, one of the primary drivers of an investment's value.
Most indicators from Compugen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Compugen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.At this time, Compugen's Tax Provision is very stable compared to the past year. As of the 26th of January 2026, Enterprise Value is likely to grow to about 146.1 M, while Selling General Administrative is likely to drop about 6.8 M.
 2023 2024 2025 2026 (projected)
Net Interest Income3.2M5.2M6.0M6.3M
Interest Income3.0M3.5M4.0M4.2M

Compugen fundamental ratios Correlations

0.770.670.880.360.01-0.70.420.040.37-0.020.830.280.740.730.36-0.610.750.480.50.910.73-0.260.270.710.64
0.770.890.580.260.42-0.90.6-0.360.010.290.770.330.930.930.56-0.690.920.70.640.880.93-0.250.460.960.84
0.670.890.350.130.32-0.820.52-0.250.010.220.680.460.860.90.83-0.630.870.920.810.830.88-0.190.760.890.67
0.880.580.350.44-0.18-0.460.340.210.52-0.140.760.10.550.51-0.01-0.430.560.120.240.770.52-0.3-0.110.50.51
0.360.260.130.44-0.26-0.340.320.30.06-0.270.39-0.10.350.32-0.08-0.040.37-0.010.490.340.33-0.52-0.350.280.28
0.010.420.32-0.18-0.26-0.350.08-0.99-0.430.620.10.080.340.360.33-0.50.290.340.120.140.350.050.350.440.52
-0.7-0.9-0.82-0.46-0.34-0.35-0.470.29-0.01-0.28-0.69-0.29-0.95-0.94-0.580.66-0.95-0.69-0.67-0.77-0.950.17-0.43-0.93-0.73
0.420.60.520.340.320.08-0.47-0.070.00.090.280.350.410.410.08-0.050.440.240.310.410.41-0.350.060.480.31
0.04-0.36-0.250.210.3-0.990.29-0.070.45-0.62-0.02-0.09-0.26-0.28-0.250.46-0.21-0.26-0.03-0.07-0.27-0.06-0.29-0.36-0.46
0.370.010.010.520.06-0.43-0.010.00.450.070.23-0.080.090.06-0.10.060.11-0.070.010.190.07-0.31-0.11-0.03-0.09
-0.020.290.22-0.14-0.270.62-0.280.09-0.620.070.01-0.040.250.250.22-0.280.230.220.040.00.26-0.040.230.310.4
0.830.770.680.760.390.1-0.690.28-0.020.230.01-0.110.830.830.53-0.620.830.60.630.930.82-0.160.330.820.84
0.280.330.460.1-0.10.08-0.290.35-0.09-0.08-0.04-0.110.20.210.21-0.280.210.310.230.270.21-0.150.390.2-0.09
0.740.930.860.550.350.34-0.950.41-0.260.090.250.830.20.990.66-0.71.00.760.740.881.0-0.180.490.980.82
0.730.930.90.510.320.36-0.940.41-0.280.060.250.830.210.990.72-0.720.990.810.790.881.0-0.220.560.980.82
0.360.560.83-0.01-0.080.33-0.580.08-0.25-0.10.220.530.210.660.72-0.540.670.980.80.590.70.020.930.680.52
-0.61-0.69-0.63-0.43-0.04-0.50.66-0.050.460.06-0.28-0.62-0.28-0.7-0.72-0.54-0.69-0.59-0.5-0.71-0.710.2-0.43-0.73-0.72
0.750.920.870.560.370.29-0.950.44-0.210.110.230.830.211.00.990.67-0.690.770.770.881.0-0.230.50.970.8
0.480.70.920.12-0.010.34-0.690.24-0.26-0.070.220.60.310.760.810.98-0.590.770.840.70.79-0.050.90.780.6
0.50.640.810.240.490.12-0.670.31-0.030.010.040.630.230.740.790.8-0.50.770.840.690.77-0.440.610.720.57
0.910.880.830.770.340.14-0.770.41-0.070.190.00.930.270.880.880.59-0.710.880.70.690.88-0.210.470.870.79
0.730.930.880.520.330.35-0.950.41-0.270.070.260.820.211.01.00.7-0.711.00.790.770.88-0.190.530.980.82
-0.26-0.25-0.19-0.3-0.520.050.17-0.35-0.06-0.31-0.04-0.16-0.15-0.18-0.220.020.2-0.23-0.05-0.44-0.21-0.190.12-0.16-0.16
0.270.460.76-0.11-0.350.35-0.430.06-0.29-0.110.230.330.390.490.560.93-0.430.50.90.610.470.530.120.520.35
0.710.960.890.50.280.44-0.930.48-0.36-0.030.310.820.20.980.980.68-0.730.970.780.720.870.98-0.160.520.87
0.640.840.670.510.280.52-0.730.31-0.46-0.090.40.84-0.090.820.820.52-0.720.80.60.570.790.82-0.160.350.87
Click cells to compare fundamentals

Compugen Account Relationship Matchups

Compugen fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets132.2M94.2M121.3M115.0M132.2M72.9M
Other Current Liab11.7M9.5M11.0M8.2M9.5M10.0M
Net Debt(5.1M)(9.1M)(12.5M)(15.3M)(13.8M)(14.5M)
Retained Earnings(422.1M)(455.8M)(474.5M)(488.8M)(439.9M)(417.9M)
Accounts Payable4.6M1.8M3.5M1.8M2.1M1.9M
Cash7.8M11.1M13.9M18.2M21.0M24.8M
Net Receivables188K317K61.3M269K309.4K293.9K
Inventory(780K)(119.3M)(6.0M)(72.6M)(65.4M)(62.1M)
Total Liab25.5M16.5M55.8M60.1M69.1M72.5M
Total Current Assets123.2M86.1M114.6M106.0M121.9M128.0M
Common Stock239K240K247K248K285.2K299.5K
Other Liab5.6M5.5M6.4M3.3M3.8M4.6M
Other Assets3.2M4.7M5.0M4.7M5.4M5.7M
Other Current Assets6.0M2.5M2.6M2.5M2.2M2.9M
Short Term Debt768K613K632K448K403.2K802.3K
Net Tangible Assets38.3M119.8M106.7M77.7M89.3M77.0M
Net Invested Capital106.7M77.7M65.6M54.9M63.2M72.8M
Net Working Capital106.1M74.2M88.3M85.8M98.7M78.8M
Capital Stock239K240K247K248K285.2K244.5K
Today, most investors in Compugen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Compugen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Compugen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.49

At this time, Compugen's Price Earnings To Growth Ratio is very stable compared to the past year.

Compugen January 26, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Compugen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Compugen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Compugen based on widely used predictive technical indicators. In general, we focus on analyzing Compugen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Compugen's daily price indicators and compare them against related drivers.
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.30)
Revenue Per Share
0.075
Quarterly Revenue Growth
(0.89)
Return On Assets
(0.18)
Return On Equity
(0.53)
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.